[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592544":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":258,"collaborators":25,"id":260,"slug":261,"hasResults":262,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":25,"eligibilityCriteria":266,"healthyVolunteers":262,"sex":267,"minAge":268,"maxAge":25,"enrollmentInfo":269,"targetDuration":25,"studyType":272,"phases":273,"briefSummary":275,"conditions":276,"keywords":25,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":287},{"fullName":5,"class":6},"Kumquat Biosciences Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Monotherapy Dose Escalation","EXPERIMENTAL","Drug: KQB168 - Oral KQB168",[13],"Drug: KQB168",{"label":15,"type":10,"description":16,"interventionNames":17},"Combo Therapy Dose Escalation","Drug: KQB168 - Oral KQB168 Drug: pembrolizumab - Intravenous pembrolizumab",[13,18],"Drug: Pembrolizumab",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","KQB168","Oral KQB168",[15,9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Pembrolizumab","Intravenous pembrolizumab",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Kumquat Clinical Development","CONTACT","(858) 214-2700","kumquatstudies@kumquatbio.com",[37,56,71,86,101,116,130,145,160,175,190,204,218,229,243],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Mayo Clinic - Phoenix","RECRUITING","Phoenix","Arizona","85054","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-112.07404,33.44838,{"lat":49,"lon":48},[52],{"name":53,"role":33,"phone":54,"phoneExt":25,"email":55},"Robby Bennett","480-342-6641","bennettiii.robert@mayo.edu",{"facility":57,"status":39,"city":58,"state":59,"zip":60,"country":43,"countryCode":44,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"USC Norris Comprehensive Cancer Center","Los Angeles","California","90033",{"type":46,"coordinates":62},[63,64],-118.24368,34.05223,{"lat":64,"lon":63},[67],{"name":68,"role":33,"phone":69,"phoneExt":25,"email":70},"Stephanie Kim","323-865-0240","Stephanie.Kim2@med.usc.edu",{"facility":72,"status":39,"city":73,"state":74,"zip":75,"country":43,"countryCode":44,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Sarah Cannon Cancer Institute at HealthONE","Denver","Colorado","80218",{"type":46,"coordinates":77},[78,79],-104.9847,39.73915,{"lat":79,"lon":78},[82],{"name":83,"role":33,"phone":84,"phoneExt":25,"email":85},"Brandon Johnson","720-754-2610","brandon.johnson2@sarahcannon.com",{"facility":87,"status":39,"city":88,"state":89,"zip":90,"country":43,"countryCode":44,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Yale Cancer Center- New Haven","New Haven","Connecticut","06520",{"type":46,"coordinates":92},[93,94],-72.92816,41.30815,{"lat":94,"lon":93},[97],{"name":98,"role":33,"phone":99,"phoneExt":25,"email":100},"Priscilla Steve","203-464-5564","Priscilla.steve@yale.edu",{"facility":102,"status":39,"city":103,"state":104,"zip":105,"country":43,"countryCode":44,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Mayo Clinic - Jacksonville","Jacksonville","Florida","32224",{"type":46,"coordinates":107},[108,109],-81.65565,30.33218,{"lat":109,"lon":108},[112],{"name":113,"role":33,"phone":114,"phoneExt":25,"email":115},"Kendal Klein","904-953-3545","Klein.Kendal@mayo.edu",{"facility":117,"status":39,"city":118,"state":104,"zip":119,"country":43,"countryCode":44,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Florida Cancer Specialists - Sarasota","Sarasota","34232",{"type":46,"coordinates":121},[122,123],-82.53065,27.33643,{"lat":123,"lon":122},[126],{"name":127,"role":33,"phone":128,"phoneExt":25,"email":129},"Sarah Gwirtz","941-377-9993","sarah.gwirtz@flcancer.com",{"facility":131,"status":39,"city":132,"state":133,"zip":134,"country":43,"countryCode":44,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"University of Iowa","Iowa City","Iowa","52242",{"type":46,"coordinates":136},[137,138],-91.53017,41.66113,{"lat":138,"lon":137},[141],{"name":142,"role":33,"phone":143,"phoneExt":25,"email":144},"Jennifer Adams","319-467-6774","jennifer-adams@uiowa.edu",{"facility":146,"status":39,"city":147,"state":148,"zip":149,"country":43,"countryCode":44,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Mayo Clinic - Rochester","Rochester","Minnesota","55905",{"type":46,"coordinates":151},[152,153],-92.4699,44.02163,{"lat":153,"lon":152},[156],{"name":157,"role":33,"phone":158,"phoneExt":25,"email":159},"Siobhan Chantigian","507-738-7036","chantigian.siobhan@mayo.edu",{"facility":161,"status":39,"city":162,"state":163,"zip":164,"country":43,"countryCode":44,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":46,"coordinates":166},[167,168],-81.69541,41.4995,{"lat":168,"lon":167},[171],{"name":172,"role":33,"phone":173,"phoneExt":25,"email":174},"Heather Keaney","216-444-3409","keaneyh@ccf.org",{"facility":176,"status":39,"city":177,"state":178,"zip":179,"country":43,"countryCode":44,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"NEXT Austin","Austin","Texas","78758",{"type":46,"coordinates":181},[182,183],-97.74306,30.26715,{"lat":183,"lon":182},[186],{"name":187,"role":33,"phone":188,"phoneExt":25,"email":189},"Heather Watson","737-610-5202","hwatson@nextoncology.com",{"facility":191,"status":39,"city":192,"state":178,"zip":193,"country":43,"countryCode":44,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"Mary Crowley Cancer Research Centers","Dallas","75230",{"type":46,"coordinates":195},[196,197],-96.80667,32.78306,{"lat":197,"lon":196},[200],{"name":201,"role":33,"phone":202,"phoneExt":25,"email":203},"Sangavi Manalan","972-566-3014","sangavi.sethumanalan@scri.com",{"facility":205,"status":39,"city":206,"state":178,"zip":207,"country":43,"countryCode":44,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"UT MD Anderson Cancer Center - Houston","Houston","77030",{"type":46,"coordinates":209},[210,211],-95.36327,29.76328,{"lat":211,"lon":210},[214],{"name":215,"role":33,"phone":216,"phoneExt":25,"email":217},"Anupama Madhyannapu","346-722-9365","admadhyannapu@mdanderson.org",{"facility":219,"status":39,"city":206,"state":178,"zip":220,"country":43,"countryCode":44,"cosmosGeoPoint":221,"geoPoint":223,"contacts":224},"NEXT Huston","77054",{"type":46,"coordinates":222},[210,211],{"lat":211,"lon":210},[225],{"name":226,"role":33,"phone":227,"phoneExt":25,"email":228},"Emma Morales","(832) 384-7912","emorales@nextoncology.com",{"facility":230,"status":39,"city":231,"state":178,"zip":232,"country":43,"countryCode":44,"cosmosGeoPoint":233,"geoPoint":237,"contacts":238},"NEXT Oncology","San Antonio","78229",{"type":46,"coordinates":234},[235,236],-98.49363,29.42412,{"lat":236,"lon":235},[239],{"name":240,"role":33,"phone":241,"phoneExt":25,"email":242},"Jordan Georg","(210) 580-9521","jgeorg@nextoncology.com",{"facility":244,"status":39,"city":245,"state":246,"zip":247,"country":43,"countryCode":44,"cosmosGeoPoint":248,"geoPoint":252,"contacts":253},"NEXT Virginia","Fairfax","Virginia","22031",{"type":46,"coordinates":249},[250,251],-77.30637,38.84622,{"lat":251,"lon":250},[254],{"name":255,"role":33,"phone":256,"phoneExt":25,"email":257},"Referral Coordinator","(703) 783-4518","mdelarosa@nextoncology.com",{"type":259,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100592544","phase-1-a-study-to-investigate-the-safety-and-efficacy-of-kqb168-as-monotherapy-and-in-combination-in-participants-with-advanced-solid-malignancies-100592544",false,"NCT06994806","A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","A Phase 1, Open-label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB168 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Malignancies","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of solid tumor malignancy.\n* Unresectable or metastatic disease that has progressed on immunotherapy.\n* No available treatment with curative intent\n* Adequate organ function\n* Measurable disease per RECIST v1.1\n\nExclusion Criteria:\n\n* Active primary central nervous system tumors\n* Cardiac abnormalities\n* History of lung diseases\n* Any condition that may impair drug absorption or prevent oral dosing\n* Known history of immune-mediated colitis and uncontrolled autoimmune diseases","ALL","18 Years",{"count":270,"type":271},84,"ESTIMATED","INTERVENTIONAL",[274],"PHASE1","The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are:\n\n* What is the safe dose of KQB168 by itself or in combination with pembrolizumab?\n* Does KQB168 alone or in combination with pembrolizumab decrease the size of the tumor?\n* What happens to KQB168 in the body?\n\nParticipants will:\n\n* Take KQB168 daily, alone or in combination with pembrolizumab\n* Visit the clinic about 8 times in the first 8 weeks, and then once every 3 weeks after that",[277],"Solid Tumor Malignancies","2026-02-27",{"date":280,"type":281},"2026-03-03","ACTUAL",{"date":283,"type":281},"2025-06-24",{"date":285,"type":271},"2028-05-31",{"name":5,"class":6},15]